Pulmonary embolism, coagulation
| Zeile 31: | Zeile 31: | ||
{{tp|p=32388068|t=2020. Thrombotic complications in critically ill patients with COVID 19 |pdf=|usr=}} | {{tp|p=32388068|t=2020. Thrombotic complications in critically ill patients with COVID 19 |pdf=|usr=}} | ||
{{tp|p=32291094|t=2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 |pdf=|usr=}} | {{tp|p=32291094|t=2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=32374544|t=2020. Risque thrombotique veineux induit par le SARS-CoV-2 : prevalence, recommandations et perspectives |pdf=|usr=}} | ||
| + | |||
| + | *'''papers on Hypoxemia''' | ||
| + | {{tp|p=32359410|t=ä. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT |pdf=|usr=}} | ||
| + | {{tp|p=C7177114|t=2020. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes |pdf=|usr=}} | ||
| + | {{tp|p=32376101|t=2020. Association Between Hypoxemia and Mortality in Patients With COVID-19 |pdf=|usr=}} | ||
| Zeile 36: | Zeile 42: | ||
{{tp|p=32338320|t=ä. Covid-19 treatment update: follow the scientific evidence |pdf=|usr=}} | {{tp|p=32338320|t=ä. Covid-19 treatment update: follow the scientific evidence |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32302456|t=2020. Potential of heparin and nafamostat combination therapy for COVID-19 |pdf=|usr=}} | {{tp|p=32302456|t=2020. Potential of heparin and nafamostat combination therapy for COVID-19 |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32378030|t=ä. COVID-19-Related Stroke |pdf=|usr=}} | {{tp|p=32378030|t=ä. COVID-19-Related Stroke |pdf=|usr=}} | ||
| Zeile 98: | Zeile 53: | ||
{{tp|p=32283877|t=2020. Prognostic value of myocardial injury in patients with COVID-19 |pdf=|usr=}} | {{tp|p=32283877|t=2020. Prognostic value of myocardial injury in patients with COVID-19 |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
Version vom 11. Juni 2020, 10:47 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
Since there are many organ manifestations of Hypercoagulation, subcategorization and tranccategorization was applied.
- Venous thrombosis
- Pulmonary embolism
- Cerebral embolism
- Myocardial infarction
- Arterial embolism
- Microembolism
- Hypercoagulation
- Antiphospholipid antibodies
- Disseminated intravascular coagulation
- Bleeding
- Labwork of Thrombembolism
- Prophylaxis of Thrombembolism
The unifying concept behind is Dysendoheliosis with the components Coagulation /Microthrombi, proliferative or cytopathic obstructive Endotheliosis and mediator production as well as failure of the mitigating systems and secondary vasculitis.
- papers on various thromboembolic maifestations
32281926 2020. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)
32347323 ä. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation
32360371 ä. Thromboembolic events in patients with SARS-CoV-2
C7146714 ä. Incidence of thrombotic complications in critically ill ICU patients with COVID-19
32324101 2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands
32133825 2020. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19
32402423 2020. Ten key points that vascular doctors learned very quickly about COVID-19
32381264 2020. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis
32388068 2020. Thrombotic complications in critically ill patients with COVID 19
32291094 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19
32374544 2020. Risque thrombotique veineux induit par le SARS-CoV-2 : prevalence, recommandations et perspectives
- papers on Hypoxemia
32359410 ä. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT
C7177114 2020. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes
32376101 2020. Association Between Hypoxemia and Mortality in Patients With COVID-19
32338320 ä. Covid-19 treatment update: follow the scientific evidence
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19
32378030 ä. COVID-19-Related Stroke
32283877 2020. Prognostic value of myocardial injury in patients with COVID-19
